Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
about
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47Dinosaurs and ancient civilizations: reflections on the treatment of cancerRadioprotection in normal tissue and delayed tumor growth by blockade of CD47 signalingCD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interestNeoplasia: the second decade.Molecular regulation of tumor angiogenesis and perfusion via redox signaling.A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivosFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.Efficiency of calcium phosphate composite nanoparticles in targeting Ehrlich carcinoma cells transplanted in mice.Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.CD36 as a therapeutic target for endothelial dysfunction in stroke.Original insights on thrombospondin-1-related antireceptor strategies in cancer.Identification of TAX2 peptide as a new unpredicted anti-cancer agent.Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury.Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesThe War on Cancer rages on.Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1.Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.
P2860
Q24627155-248A6E1E-DCC1-4C23-8B7E-1A5C0C920C8CQ24628746-8FD9969A-29C2-4014-8CA3-0B76166B21D1Q24657627-0FFD115C-04BA-4076-BA52-82548D2A9362Q28270624-468937B9-142D-4E9E-AE5D-271CDAE8DCACQ30484000-54B4CDC8-6F1E-4E3D-B101-CAF21F377FCFQ33572306-3848B0D6-30C1-4E1D-BE54-228737339242Q33576606-2443D6D7-E90E-4D26-A3DF-E9FCBF39983CQ34904445-8A5E07A5-7ADE-482D-9831-BB286834314FQ35914285-A31D334B-7AED-4D0E-94B9-B37323B4906AQ36011859-1C854623-FF70-4990-8B23-245CE92ACF7AQ36139754-FFD2E23D-37F3-4BF3-A85F-31DBEE994106Q36221374-2FE93787-720D-4AC9-9460-9BC0EB5B76D4Q36228487-7C8461CC-0B45-4382-92A8-5823FD28D088Q36891538-8DF7E0F1-91D1-43F3-B84A-8EF1113AB0C0Q37385797-68D62E4F-78BE-4F5A-94F0-1A9907AAE904Q37478602-42573C14-4355-4C10-8359-2CA676DF8089Q39238169-EA2217C8-BEE5-47B3-BFDB-6BC26D013468Q39246000-844E0EEB-D75E-47BA-8551-4628DC8C813EQ48253400-7C653566-2891-4513-AF70-F67F8F6F586B
P2860
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@ast
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@en
type
label
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@ast
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@en
prefLabel
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@ast
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
@en
P2093
P2860
P356
P1433
P1476
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow
@en
P2093
Caitlin S Shannon
David A Wink
Fuminori Hyodo
Jeff S Isenberg
Lisa A Ridnour
Murali C Krishna
P2860
P304
P356
10.1593/NEO.08264
P577
2008-08-01T00:00:00Z